Annexon (ANNX) Wells Fargo 20th Annual Healthcare Conference 2025 summary

Strategic program overview

• Focus on pioneering first-in-kind therapies targeting classical complement for immune inflammation across body, brain, and eye, with landmark progress in Guillain-Barré syndrome (GBS), geographic atrophy (GA), and a novel small molecule program.

• GBS program demonstrated unprecedented efficacy, with 90% of patients improving by week one in phase III trials; robust data package includes placebo-controlled studies, drug-drug interaction, and real-world evidence.

• GA program is the only vision-sparing approach globally, with PRIME designation in Europe and a large phase III trial completed ahead of schedule.

• Small molecule C1s inhibitor program aims to disrupt established antibody markets by offering a convenient oral therapy for neuromuscular and antibody-mediated diseases.

Regulatory and clinical development updates

• EMA granted orphan drug designation for GBS based on proof-of-concept and real-world evidence; MAA filing anticipated by Q1 2026.

• U.S. regulatory pathway for GBS involves ongoing discussions with FDA, with a Type C meeting expected in the fall to clarify generalizability concerns; communication to follow based on meeting outcomes.

• FORWARD study in the U.S. is open-label, focusing on pediatric enrollment for EMA and understanding real-world patient management; not FDA-mandated but valuable for commercialization.

• GA phase III trial closely mirrors successful phase II, with enriched enrollment based on baseline vision; primary endpoint is BCVA 15-letter loss, the gold standard for vision preservation.

• Small molecule program (1502) has advanced through formulation improvements, now in phase II proof-of-concept with promising PK/PD data; final go/no-go decision will depend on tolerability and efficacy in fasted patients.

Commercialization and market opportunity

• Intends to monetize ex-U.S. GBS rights by partnering with established hospital-based neuro businesses in Europe; active discussions ongoing.

• U.S. GBS market is highly concentrated, enabling targeted commercialization; focus on payer engagement and hospital education to streamline patient flow and maximize value proposition.

• EU GBS market estimated at 15,000 patients annually, with most currently treated with IVIG; health economics analysis to be released later this year to support value-based pricing.

• GA program aims for global approval with a differentiated label for vision preservation, supported by strong regulatory alignment in both U.S. and Europe.

• Small molecule C1s inhibitor could offer a significant convenience and efficacy advantage in neuromuscular diseases, with commercial differentiation from entrenched antibody therapies.